Mammographic density, MRI background parenchymal enhancement and breast cancer risk

Annals of Oncology

Volumn 24, Issue SUPPL.B, 2013, Pages

  Pike, M C ^a,b   Pearce, C L ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Breast background parenchymal enhancement; Breast cancer; Breast MRI; Mammographic density

Indexed keywords

ANASTROZOLE; COLLAGEN; CONTRAST MEDIUM; TAMOXIFEN;

ARTICLE; AUTOPSY; BACKGROUND PARENCHYMAL ENHANCEMENT; BREAST; BREAST CALCIFICATION; BREAST CANCER; BREAST EPITHELIUM; BREAST TUMOR; CANCER RISK; CELL COUNT; CLINICAL PRACTICE; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; EPITHELIUM CELL; FIBROGLANDULAR TISSUE; HUMAN; IMAGE ANALYSIS; MAMMOGRAPHIC DENSITY; MAMMOGRAPHY; MENOPAUSE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RADIOLOGICAL PARAMETERS; RISK ASSESSMENT; RISK FACTOR; TREATMENT DURATION; TREATMENT RESPONSE;

BREAST BACKGROUND PARENCHYMAL ENHANCEMENT; BREAST CANCER; BREAST MRI; MAMMOGRAPHIC DENSITY;

BREAST; BREAST NEOPLASMS; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MAMMARY GLANDS, HUMAN; MAMMOGRAPHY; RISK FACTORS;

EID: 84886295529     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt310     Document Type: Article

References (43)

1. Boyd NF, Lockwood GA, Byng JW et al. Mammographic densities and breast cancer risk. Cancer Epidemiol Biomarkers Prev 1998; 7: 1133-1144.
2. Lee NA, Rusinek H, Weinreb J et al. Fatty and fibroglandular tissue volumes in the breasts of women 20-83 years old: comparison of X-ray mammography and computer-assisted MR imaging. Am J Roentgenol 1997; 168: 501-506.
3. King V, Brooks JD, Bernstein JL et al. Background parenchymal enhancement at breast MR imaging and breast cancer risk. Radiology 2011; 260: 50-60.
4. Wolfe JN. Breast patterns as an index of risk for developing breast cancer. Am J Roentgenol 1976; 126: 1130-1137.
5. Wolfe JN. Risk for breast cancer development determined by mammographic parenchymal pattern. Cancer 1976; 37: 2486-2492.
6. Wolfe JN. Breast parenchymal patterns and their changes with age. Radiology 1976; 121: 545-552.
7. Boyd NF, Byng JW, Jong RA et al. Quantitative classification of mammographic densities and breast cancer risk: results from the Canadian National Breast Screening Study. J Natl Cancer Inst 1995; 87: 670-675.
8. Stone J, Ding J, Warren RM et al. Using mammographic density to predict breast cancer risk: dense area or percentage dense area. Breast Cancer Res 2010; 12: R97.
9. Wei J, Chan HP, Helvie MA et al. Correlation between mammographic density and volumetric fibroglandular tissue estimated on breast MR images. Med Phys 2004; 31: 933-942.
10. Thompson D, Leach M, Kwan-Lim G et al. Assessing the usefulness of a novel MRIbased breast density estimation algorithm in a cohort of women at high genetic risk of breast cancer: the UK MARIBS study. Breast Cancer Res 2009; 11: R80.
11. Klifa C, Carballido-Gamio J, Wilmes L et al. Magnetic resonance imaging for secondary assessment of breast density in a high-risk cohort. Magn Reson Imaging 2010; 28: 8-15.
12. Nie K, Chen JH, Chan S et al. Development of a quantitative method for analysis of breast density based on three-dimensional breast MRI. Med Phys 2008; 35: 5253-5262.
13. Boyd NF, Dite GS, Stone J et al. Heritability of mammographic density, a risk factor for breast cancer. N Engl J Med 2002; 347: 886-894.
14. Steinberg KK, Smith SJ, Stroup DF et al. Comparison of effect estimates from a meta-analysis of summary data from published studies and from a meta-analysis using individual patient data for ovarian cancer studies. Am J Epidemiol 1997; 145: 917-925.
15. Pike MC, Krailo MD, Henderson BE et al. 'Hormonal' risk factors, 'breast tissue age' and the age-incidence of breast cancer. Nature 1983; 303: 767-770.
16. Pike MC. Age-related factors in cancers of the breast, ovary and endometrium. J Chronic Dis 1987; 40(Suppl. 2): 59S-69S.
17. Trichopoulos D, MacMahon B, Cole P. Menopause and breast cancer risk. J Natl Cancer Inst 1972; 48: 605-613.
18. Pike MC, Spicer DV, Dahmoush L et al. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev 1993; 15: 17-35.
19. Boyd N, Martin L, Stone J et al. A longitudinal study of the effects of menopause on mammographic features. Cancer Epidemiol Biomarkers Prev 2002; 11: 1048-1053.
20. Martin LJ, Boyd NF. Mammographic density. Potential mechanisms of breast cancer risk associated with mammographic density: hypotheses based on epidemiological evidence. Breast Cancer Res 2008; 10: 201.
21. Bartow SA, Pathak DR, Mettler FA. Radiographic microcalcification and parenchymal patterns as indicators of histologic "high-risk" benign breast disease. Cancer 1990; 66: 1721-1725.
22. Bartow SA, Pathak DR, Mettler FA et al. Breast mammographic pattern: a concatenation of confounding and breast cancer risk factors. Am J Epidemiol 1995; 142: 813-819.
23. Li T, Sun L, Miller N et al. The association of measured breast tissue characteristics with mammographic density and other risk factors for breast cancer. Cancer Epidemiol Biomarkers Prev 2005; 14: 343-349.
24. Ursin G, Hovanessian-Larsen L, Parisky YR et al. Greatly increased occurrence of breast cancers in areas of mammographically dense tissue. Breast Cancer Res 2005; 7: R605.
25. Hawes D, Downey S, Pearce CL et al. Dense breast stromal tissue shows greatly increased concentration of breast epithelium but no increase in its proliferative activity. Breast Cancer Res 2006; 8: R24.
26. Cuzick J, Sestak I, Pinder SE et al. Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial. Lancet Oncol 2011; 12: 21-29.
27. Chung K, Hovanessian-Larsen LJ, Hawes D et al. Breast epithelial cell proliferation is markedly increased with short-term high levels of endogenous estrogen secondary to controlled ovarian hyperstimulation. Breast Cancer Res Treat 2012; 132: 653-660.
28. Kerlikowske K, Phipps AI. Breast density influences tumor subtypes and tumor aggressiveness. J Natl Cancer Inst 2011; 103: 1143-1145.
29. Phipps AI, Buist DS, Malone KE et al. Reproductive history and risk of three breast cancer subtypes defined by three biomarkers. Cancer Causes Control 2011; 22: 399-405.
30. Pike MC, Ross RK, Lobo RA et al. LHRH agonists and the prevention of breast and ovarian cancer. Br J Cancer 1989; 60: 142-148.
31. Spicer DV, Ursin G, Parisky YR et al. Changes in mammographic densities induced by a hormonal contraceptive designed to reduce breast cancer risk. J Natl Cancer Inst 1994; 86: 431-436.
32. Weitzel JN, Buys SS, Sherman WH et al. Reduced mammographic density with use of a gonadotropin-releasing hormone agonist-based chemoprevention regimen in BRCA1 carriers. Clin Cancer Res 2007; 13: 654-658.
33. Gram IT, Ursin G, Spicer DV et al. Reversal of gonadotropin-releasing hormone agonist induced reductions in mammographic densities on stopping treatment. Cancer Epidemiol Biomarkers Prev 2001; 10: 1117-1120.
34. Morris EA. Diagnostic breast MR imaging: current status and future directions. Radiol Clin North Am 2007; 45: 863-880, vii.
35. Kuhl C. The current status of breast MR imaging. Part I. Choice of technique, image interpretation, diagnostic accuracy, and transfer to clinical practice. Radiology 2007; 244: 356-378.
36. King V, Gu Y, Kaplan JB et al. Impact of menopausal status on background parenchymal enhancement and fibroglandular tissue on breast MRI. Eur Radiol 2012; 22: 2641-2647.
37. King V, Kaplan J, Pike MC et al. Impact of tamoxifen on amount of fibroglandular tissue, background parenchymal enhancement, and cysts on breast magnetic resonance imaging. Breast J 2012; 18: 527-534.
38. King V, Goldfarb SB, Brooks JD et al. Effect of aromatase inhibitors on background parenchymal enhancement and amount of fibroglandular tissue at breast MR imaging. Radiology 2012; 264: 670-678.
39. Atkinson C, Warren R, Bingham SA et al. Mammographic patterns as a predictive biomarker of breast cancer risk: effect of tamoxifen. Cancer Epidemiol Biomarkers Prev 1999; 8: 863-866.
40. Brisson J, Brisson B, Cote G et al. Tamoxifen and mammographic breast densities. Cancer Epidemiol Biomarkers Prev 2000; 9: 911-915.
41. Cuzick J, Warwick J, Pinney E et al. Tamoxifen and breast density in women at increased risk of breast cancer. J Natl Cancer Inst 2004; 96: 621-628.
42. Cuzick J, Warwick J, Pinney E et al. Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case-control study. J Natl Cancer Inst 2011; 103: 744-752.
43. Fisher B, Constantino JP, Wickerham L et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 1998; 90: 1371-1388.